Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan

Naoto Yokogawa; Ryoko Sakai; Masakazu Matsushita; Masaki Shimizu; Yuzaburo Inoue; Eisuke Inoue; Ken Yamaji; Masaaki Mori; Takako Miyamae

doi:10.1093/mr/roae072

journal article Aug 21, 2024

Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan

Naoto Yokogawa

Ryoko Sakai

Masakazu Matsushita Masaki Shimizu

Yuzaburo Inoue

Eisuke Inoue Ken Yamaji Masaaki Mori

Takako Miyamae

Modern Rheumatology Vol. 35 No. 2 pp. 294-299 · Oxford University Press (OUP)

View at Publisher Save 10.1093/mr/roae072

Abstract

ABSTRACT

Objectives
The aim of this study was to evaluate the status of the global standardization of, and prefectural differences in, systemic lupus erythematosus (SLE) treatments in Japan.

Methods
The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan) was used. A patient with SLE was defined as having a disease with ICD-10 code M321 or M329 between April 2019 and March 2020, for which oral corticosteroids, immunosuppressive agents, or biologic agents were prescribed at least once during a given month. SLE treatments were evaluated by treatment centre type and prefecture.

Results
In total, 74,277 patients met the definition of SLE. The SLE prevalence was 60 per 100,000 (range: 47–102 per 100,000 by prefecture). Nationwide, 79.4% of the patients (range: 52.1–93.3% by prefecture) visited a specialized treatment centre (STC); 37.4% (range: 26.4–51.3% by prefecture) received only oral corticosteroids, with fewer of these patients visiting an STC than a non-STC (34.8% and 49.7%, P &lt; .001); and 21.4% (range: 10.7–35.0%) received hydroxychloroquine, with more of these patients visiting an STC than a non-STC (23.0% and 13.5%; P &lt; .001).

Conclusions
The NDB Japan demonstrated the delayed global standardization of, and prefectural disparity in, SLE treatments in Japan.

Topics

No keywords indexed for this article. Browse by subject →

References

17

[1]

van Vollenhoven "Treat-to-target in systemic lupus erythematosus: recommendations from an international task force" Ann Rheum Dis (2014) 10.1136/annrheumdis-2013-205139

[2]

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno et al.

Annals of the Rheumatic Diseases 2019 10.1136/annrheumdis-2019-215089

[3]

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen et al.

Annals of the Rheumatic Diseases 2024 10.1136/ard-2023-224762

[4]

Gordon "The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults" Rheumatology (2018) 10.1093/rheumatology/kex286

[5]

The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus

Chi Chiu Mok, Laniyati Hamijoyo, Nuntana Kasitanon et al.

The Lancet Rheumatology 2021 10.1016/s2665-9913(21)00009-6

[6]

Improving access to SLE therapies in low and middle-income countries

Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Manuel F Ugarte-Gil

Rheumatology 2023 10.1093/rheumatology/keac530

[7]

Kishimoto "Use of hydroxychloroquine in Japan" J Rheumatol (2012) 10.3899/jrheum.111569

[8]

Yokogawa "Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial" Arthritis Rheumatol (2017) 10.1002/art.40018

[9]

Nakajima "Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan" Int J Rheum Dis (2020) 10.1111/1756-185x.13974

[10]

Nakajima "Geographic variations in rheumatoid arthritis treatment in Japan: a nationwide retrospective study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan" Mod Rheumatol (2022) 10.1080/14397595.2021.1910615

[11]

Moores "A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data" Vaccine (2013) 10.1016/j.vaccine.2013.06.104

[12]

Sakai "The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine" Lupus (2020) 10.1177/0961203320952853

[13]

Lee "Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus" Sci Rep (2023)

[14]

Brunner "Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA" Lupus Sci Med (2023) 10.1136/lupus-2022-000817

[15]

Miyasaka "Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study" Mod Rheumatol (2009) 10.3109/s10165-009-0218-5

[16]

Mok "Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up" Ann Rheum Dis (2016) 10.1136/annrheumdis-2014-206456

[17]

Miyazaki "Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study" J Med Econ (2020) 10.1080/13696998.2020.1740236

Metrics

3

Citations

17

References

Details

Published: Aug 21, 2024
Vol/Issue: 35(2)
Pages: 294-299
License: View

Authors

N

Naoto Yokogawa

Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo,

R

Ryoko Sakai

Department of Public Health and Epidemiology, Meiji Pharmaceutical University , Tokyo,; Department of Rheumatology, Tokyo Women’s Medical University School of Medicine , Tokyo,

M

Masakazu Matsushita

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo,

M

Masaki Shimizu

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,

Y

Yuzaburo Inoue

Department of General Medical Science, Graduate School of Medicine, Chiba University , Chiba,; Department of Allergy and Rheumatology, Chiba Children’s Hospital , Chiba,

E

Eisuke Inoue

Department of Rheumatology, Tokyo Women’s Medical University School of Medicine , Tokyo,; Showa University Research Administration Center, Showa University , Tokyo,

K

Ken Yamaji

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo,

M

Masaaki Mori

Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo,

T

Takako Miyamae

Department of Rheumatology, Tokyo Women’s Medical University School of Medicine , Tokyo,

Cite This Article

Naoto Yokogawa, Ryoko Sakai, Masakazu Matsushita, et al. (2024). Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Modern Rheumatology, 35(2), 294-299. https://doi.org/10.1093/mr/roae072

Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: A nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan

You May Also Like